Gene therapy of skeletal muscle disorders using viral vectors

Muscle

Volumn 2, Issue , 2012, Pages 1045-1051

  Arnett, Andrea L H ^a,b   Ramos, Julian N ^a   Chamberlain, Jeffrey S ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882907044     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381510-1.00076-4     Document Type: Chapter

References (62)

1. Doerfler W. Adenovirus DNA, the viral genome and its expression 1986, Martinus NijhoffPublishing, Boston, MA. W. Doerfler, Y. Becker, J. Hadar (Eds.).
2. Wilson J.M. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996, 334:1185-1187.
3. Brown B.D., Shi C.X., Powell S., Hurlbut D., Graham F.L., Lillicrap D. Helper-dependent adenoviral vectors mediate therapeutic Factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 2004, 103:804-810.
4. Ehrhardt A., Xu H., Dillow A.M., Bellinger D.A., Nichols T.C., Kay M.A. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia b without liver toxicity or thrombocytopenia. Blood 2003, 102:2403-2411.
5. Huard J., Feero W.G., Watkins S.C., Hoffman E.P., Rosenblatt D.J., Glorioso J.C. The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers. J Virol 1996, 70:8117-8123.
6. Nalbantoglu J., Pari G., Karpati G., Holland P.C. Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum Gene Ther 1999, 10:1009-1019.
7. Yang Y., Jooss K.U., Su Q., Ertl H.C., Wilson J.M. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996, 3:137-144.
8. Alba R., Bosch A., Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005, 12(Suppl. 1):S18-S27.
9. DelloRusso C., Scott J.M., Hartigan-O'Connor D., Salvatori G., Barjot C., Robinson A.S., et al. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci USA 2002, 99:12979-12984.
10. Hartigan-O'Connor D., Barjot C., Salvatori G., Chamberlain J.S. Generation and growth of gutted adenoviral vectors. Methods Enzymol. 2002, 346:224-246.
11. Hartigan-O'Connor D., Kirk C.J., Crawford R., Mule J.J., Chamberlain J.S. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther 2001, 4:525-533.
12. Hauser M.A., Robinson A., Hartigan-O'Connor D., Williams-Gregory D.A., Buskin J.N., Apone S., et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol Ther 2000, 2:16-25.
13. Escors D., Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) 2010, 58:107-119.
14. Vogt V.M., Simon M.N. Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy. J Virol 1999, 73:7050-7055.
15. Li S., Kimura E., Fall B.M., Reyes M., Angello J.C., Welikson R., et al. Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Ther 2005, 12:1099-1108.
16. Peng K.W., Pham L., Ye H., Zufferey R., Trono D., Cosset F.L., et al. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther 2001, 8:1456-1463.
17. MacKenzie T.C., Kobinger G.P., Louboutin J.P., Radu A., Javazon E.H., Sena-Esteves M., et al. Transduction of satellite cells after prenatal intramuscular administration of lentiviral vectors. J Gene Med 2005, 7:50-58.
18. Talbot G.E., Waddington S.N., Bales O., Tchen R.C., Antoniou M.N. Desmin-regulated lentiviral vectors for skeletal muscle gene transfer. Mol Ther 2010, 18:601-608.
19. Kimura E., Li S., Gregorevic P., Fall B.M., Chamberlain J.S. Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression. Mol Ther 2010, 18:206-213.
20. Baum C. Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol 2007, 14:337-342.
21. Cavazzana-Calvo M., Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet?. J Clin Invest 2007, 117:1456-1465.
22. Kobinger G.P., Louboutin J.P., Barton E.R., Sweeney H.L., Wilson J.M. Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. Hum Gene Ther 2003, 14:1441-1449.
23. Atchison R.W., Casto B.C., Hammon W.M. Adenovirus-associated defective virus particles. Science 1965, 149:754-756.
24. Nayak S., Herzog R.W. Progress and prospects: immune responses to viral vectors. Gene Ther 2010, 17:295-304.
25. Rivera V.M., Gao G.P., Grant R.L., Schnell M.A., Zoltick P.W., Rozamus L.W., et al. Long-term pharmacologically regulated expression of erythropoietin in primates following aav-mediated gene transfer. Blood 2005, 105:1424-1430.
26. Gregorevic P., Blankinship M.J., Allen J.M., Crawford R.W., Meuse L., Miller D.G., et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004, 10:828-834.
27. Schultz B.R., Chamberlain J.S. Recombinant adeno-associated virus transduction and integration. Mol Ther 2008, 16:1189-1199.
28. Gregorevic P., Allen J.M., Minami E., Blankinship M.J., Haraguchi M., Meuse L., et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006, 12:787-789.
29. Wang Z., Zhu T., Qiao C., Zhou L., Wang B., Zhang J., et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005, 23:321-328.
30. Pacak C.A., Mah C.S., Thattaliyath B.D., Conlon T.J., Lewis M.A., Cloutier D.E., et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006, 99:e3-e9.
31. Zincarelli C., Soltys S., Rengo G., Rabinowitz J.E. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008, 16:1073-1080.
32. Zincarelli C., Soltys S., Rengo G., Koch W.J., Rabinowitz J.E. Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin Transl Sci 2011, 3:81-89.
33. Nakai H., Montini E., Fuess S., Storm T.A., Grompe M., Kay M.A. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 2003, 34:297-302.
34. Inagaki K., Lewis S.M., Wu X., Ma C., Munroe D.J., Fuess S., et al. DNA palindromes with a modest arm length of greater, similar 20 base pairs are a significant target for recombinant adeno-associated virus vector integration in the liver, muscles, and heart in mice. J Virol 2007, 81:11290-11303.
35. Halbert C.L., Miller A.D., McNamara S., Emerson J., Gibson R.L., Ramsey B., et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum Gene Ther 2006, 17:440-447.
36. Emery A.E., Muntoni F. Duchenne muscular dystrophy 2003, Oxford University Press, Oxford.
37. Koenig M., Beggs A.H., Moyer M., Scherpf S., Heindrich K., Bettecken T., et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989, 45:498-506.
38. Harper S.Q., Hauser M.A., DelloRusso C., Duan D., Crawford R.W., Phelps S.F., et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002, 8:253-261.
39. Sakamoto M., Yuasa K., Yoshimura M., Yokota T., Ikemoto T., Suzuki M., et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 2002, 293:1265-1272.
40. Gregorevic P., Blankinship M.J., Allen J.M., Chamberlain J.S. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther 2008, 16:657-664.
41. Banks G.B., Judge L.M., Allen J.M., Chamberlain J.S. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet 2010, 6:e1000958.
42. Odom G.L., Gregorevic P., Allen J.M., Chamberlain J.S. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol Ther 2011, 19:36-45.
43. Arruda V.R., Stedman H.H., Nichols T.C., Haskins M.E., Nicholson M., Herzog R.W., et al. Regional intravascular delivery of AAV-2-FIX to skeletal muscle achieves long-term correction of hemophilia b in a large animal model. Blood 2005, 105:3458-3464.
44. Wang Z., Allen J.M., Riddell S.R., Gregorevic P., Storb R., Tapscott S.J., et al. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 2007, 18:18-26.
45. Wang Z., Kuhr C.S., Allen J.M., Blankinship M., Gregorevic P., Chamberlain J.S., et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007, 15:1160-1166.
46. Yuasa K., Yoshimura M., Urasawa N., Ohshima S., Howell J.M., Nakamura A., et al. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther 2007, 14:1249-1260.
47. Yuasa K., Sakamoto M., Miyagoe-Suzuki Y., Tanouchi A., Yamamoto H., Li J., et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther 2002, 9:1576-1588.
48. Gregorevic P., Schultz B.R., Allen J.M., Halldorson J.B., Blankinship M.J., Meznarich N.A., et al. Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Mol Ther 2009, 17:1427-1433.
49. Mingozzi F., Hasbrouck N.C., Basner-Tschakarjan E., Edmonson S.A., Hui D.J., Sabatino D.E., et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 2007, 110:2334-2341.
50. ToromanoffA., Cherel Y., Guilbaud M., Penaud-Budloo M., Snyder R.O., Haskins M.E., et al. Safety and efficacy of regional intravenous (R.I.) versus intramuscular (I.M.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther 2008, 16:1291-1299.
51. Rodino-Klapac L.R., Janssen P.M., Montgomery C.L., Coley B.D., Chicoine L.G., Clark K.R., et al. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J Transl Med 2007, 5:45.
52. Cox G.A., Cole N.M., Matsumura K., Phelps S.F., Hauschka S.D., Campbell K.P., et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 1993, 364:725-729.
53. Wang B., Li J., Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000, 97:13714-13719.
54. Hauser M.A., Robinson A., Hartigan-O'Connor D., Williams-Gregory D.A., Buskin J.N., Apone S., et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol Ther 2000, 2:16-25.
55. Donoviel D.B., Shield M.A., Buskin J.N., Haugen H.S., Clegg C.H., Hauschka S.D. Analysis of muscle creatine kinase gene regulatory elements in skeletal and cardiac muscles of transgenic mice. Mol Cell Biol 1996, 16:1649-1658.
56. Salva M.Z., Himeda C.L., Tai P.W., Nishiuchi E., Gregorevic P., Allen J.M., et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther 2007, 15:320-329.
57. Sun B., Young S.P., Li P., Di C., Brown T., Salva M.Z., et al. Correction of multiple striated muscles in murine pompe disease through adeno-associated virus-mediated gene therapy. Mol Ther 2008, 16:1366-1371.
58. Liu Y.L., Mingozzi F., Rodriguez-Colon S.M., Joseph S., Dobrzynski E., Suzuki T., et al. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector. Hum Gene Ther 2004, 15:783-792.
59. Richard E., Douillard-Guilloux G., Batista L., Caillaud C. Correction of glycogenosis type 2 by muscle-specific lentiviral vector. In Vitro Cell Dev Biol Anim 2008, 44:397-406.
60. Mendell J.R., Campbell K., Rodino-Klapac L., Sahenk Z., Shilling C., Lewis S., et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010, 363:1429-1437.
61. Odom G.L., Gregorevic P., Allen J.M., Finn E., Chamberlain J.S. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther 2008, 16:1539-1545.
62. Arnett A.L., Chamberlain J.R., Chamberlain J.S. Therapy for neuromuscular disorders. Curr Opin Genet Dev 2009, 19:290-297.